Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Annemieke, Cats"'
Autor:
Jonathan E. Knikman, Qinglian Zhai, Carin A. T. C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H. W. van de Poel, Caroline M. P. W. Mandigers, Ron H. N. van Schaik, Hans Gelderblom, Ron H. J. Mathijssen, Jan H. M. Schellens, Annemieke Cats, Henk-Jan Guchelaar, Jesse J. Swen
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-11 (2024)
Abstract Background The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mi
Externí odkaz:
https://doaj.org/article/b16be71c28a348628ff01bad41681526
Autor:
Charlotte I. Stroes, Sybren L. Meijer, Geert-Jan Creemers, Gerrit K.J. Hooijer, Nadia Haj Mohammad, Maartje Los, Marije Slingerland, Geke A.P. Hospers, Annemieke Cats, Laurens V. Beerepoot, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102079- (2024)
Background: HER2 targeting in esophageal adenocarcinoma (EAC) has shown potential, but often fails to show durable response. Given the contributions of the tumor immune microenvironment (TIME) to therapeutic responses, we aimed to chart the TIME char
Externí odkaz:
https://doaj.org/article/140bcec5bc5649c49d43672c34967d9a
Autor:
Irene A. Caspers, Ellis L. Eikenboom, Marta Lopez-Yurda, Nicole C.T. van Grieken, Tanya M. Bisseling, Evelien Dekker, Barbara A.J. Bastiaansen, Annemieke Cats, Monique E. van Leerdam
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102494- (2024)
Summary: Background: Lynch syndrome increases the risk of gastric cancer (GC) and duodenal cancer (DC), particularly in individuals with MLH1 and MSH2 pathogenic variants (PVs). To provide further insight into whether, and from what age, esophagogast
Externí odkaz:
https://doaj.org/article/38d196956e17415f8cb9ac5982794d93
Autor:
Leonie K. deKlerk, Ruben S. A. Goedegebuure, Nicole C. T. vanGrieken, Johanna W. vanSandick, Annemieke Cats, Jurrien Stiekema, Rosa T. van derKaaij, Arantza Farina Sarasqueta, Manon vanEngeland, Maarten A. J. M. Jacobs, Roy L. J. vanWanrooij, Donald L. van derPeet, Aaron R. Thorner, Henk M. W. Verheul, Victor L. J. L. Thijssen, Adam J. Bass, Sarah Derks
Publikováno v:
Molecular Oncology, Vol 15, Iss 4, Pp 901-914 (2021)
Identification of molecular predictive markers of response to neoadjuvant chemoradiation could aid clinical decision‐making in patients with localized oesophageal cancer. Therefore, we subjected pretreatment biopsies of 75 adenocarcinoma (OAC) and
Externí odkaz:
https://doaj.org/article/7932eb37d9894db684b21beafaa514b4
Autor:
Astrid E. Slagter, Karolina Sikorska, Cecile Grootscholten, Hanneke W. M. vanLaarhoven, Pehr Lind, Marianne Nordsmark, Elma Meershoek‐Klein Kranenbarg, Cornelis J. H. van deVelde, Nicole C. T. vanGrieken, Johanna W. vanSandick, Edwin P. M. Jansen, Marcel Verheij, Annemieke Cats
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6609-6616 (2020)
Abstract Background The occurrence of a venous thromboembolism (VTE) is common in patients with cancer. Gastric cancer has been associated with one of the highest risks for VTE. Chemotherapy, especially cisplatin has been associated with a high VTE r
Externí odkaz:
https://doaj.org/article/05752313a8664a3fa268dcfd62bb2b2b
Autor:
Alessandro Leal, Nicole C. T. van Grieken, Doreen N. Palsgrove, Jillian Phallen, Jamie E. Medina, Carolyn Hruban, Mark A. M. Broeckaert, Valsamo Anagnostou, Vilmos Adleff, Daniel C. Bruhm, Jenna V. Canzoniero, Jacob Fiksel, Marianne Nordsmark, Fabienne A. R. M. Warmerdam, Henk M. W. Verheul, Dick Johan van Spronsen, Laurens V. Beerepoot, Maud M. Geenen, Johanneke E. A. Portielje, Edwin P. M. Jansen, Johanna van Sandick, Elma Meershoek-Klein Kranenbarg, Hanneke W. M. van Laarhoven, Donald L. van der Peet, Cornelis J. H. van de Velde, Marcel Verheij, Remond Fijneman, Robert B. Scharpf, Gerrit A. Meijer, Annemieke Cats, Victor E. Velculescu
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
Identifying patients that will respond to a particular therapy remains a key challenge in precision oncology. Here, in gastric cancer, the authors show that circulating tumour DNA can predict recurrence, provided that the signal from white blood cell
Externí odkaz:
https://doaj.org/article/e873283671f243d3ba192161c80d36a7
Autor:
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 940-950 (2019)
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐
Externí odkaz:
https://doaj.org/article/8300a5fe4be74766ad22f7c77488aab7
Autor:
Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, Sandrine Marreaud, Carmela Caballero, Peter Thuss-Patience, Lothar Mueller, Annelie Elme, Markus Hermann Moehler, Uwe Martens, Yoon-Koo Kang, Sun Young Rha, Annemieke Cats, Masanori Tokunaga, Florian Lordick
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background 10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadju
Externí odkaz:
https://doaj.org/article/868882dd5c1b417b8578bb744368f13f
Autor:
Astrid E. Slagter, Marieke A. Vollebergh, Edwin P. M. Jansen, Johanna W. van Sandick, Annemieke Cats, Nicole C. T. van Grieken, Marcel Verheij
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resec
Externí odkaz:
https://doaj.org/article/027289210d3e4e96ae444e0c20ec992b
Autor:
Astrid E. Slagter, Edwin P. M. Jansen, Hanneke W. M. van Laarhoven, Johanna W. van Sandick, Nicole C. T. van Grieken, Karolina Sikorska, Annemieke Cats, Pietje Muller-Timmermans, Maarten C. C. M. Hulshof, Henk Boot, Maartje Los, Laurens V. Beerepoot, Frank P. J. Peters, Geke A. P. Hospers, Boudewijn van Etten, Henk H. Hartgrink, Mark I. van Berge Henegouwen, Grard A. P. Nieuwenhuijzen, Richard van Hillegersberg, Donald L. van der Peet, Heike I. Grabsch, Marcel Verheij
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
Abstract Background Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, pos
Externí odkaz:
https://doaj.org/article/2d1b6edcba2745a0999b71b5484c2a69